Drug Profile
HIL 214
Alternative Names: HIL-214; Norovirus bivalent vaccine - Takeda; Norovirus bivalent VLP vaccine; Norovirus GI.1/GII.4 bivalent VLP vaccine; Norovirus IM vaccine - Takeda; Norovirus intramuscular vaccine - Takeda; TAK-214Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator LigoCyte Pharmaceuticals
- Developer HilleVax; Takeda
- Class Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Norovirus infections
- Phase II Gastroenteritis
Most Recent Events
- 10 Nov 2023 HilleVax completes the phase II trial in Gastroenteritis (Prevention, In adults) in USA (IM) (NCT05972733)
- 31 Oct 2023 HilleVax completes enrolment in phase II trial for Norovirus infections (In infants, Prevention) (IM) (NCT05836012)
- 18 Aug 2023 Phase-I clinical trials in Gastroenteritis (In infants, Prevention) in Japan (IM) (NCT06007781)